返回
G
Gustave Roussy
学者数7.5K
论文数5.9K
被引数8
关联论文 (3474)
发表时间
FORTIFI-HN01: A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)FORTIFI-HN01:一项多中心、随机、双盲、II/III期研究,评估ficerafusp alfa或安慰剂联合pembrolizumab用于PD-L1阳性、复发或转移性头颈鳞状细胞癌(R/M HNSCC)的一线治疗

